Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.

EP: 1.An Overview of Neuroblastoma

EP: 2.Approaches to Diagnosing Neuroblastoma

EP: 3.Role of CURIE Scores in the Treatment and Management of Neuroblastoma

EP: 4.Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

EP: 5.Differentiating Refractory and Relapsed Neuroblastoma

EP: 6.Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

Now Viewing

EP: 7.Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

EP: 8.Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

EP: 9.Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

EP: 10.Future Perspectives in the Treatment of Neuroblastoma

Related Videos